"versionIdentifier","uuid:ID","id","instanceType","rationale"
"2","ea893501-38b9-4abc-9e42-50f3a088ac7d","StudyVersion_1","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
